BrainStorm Granted Patents for Allogeneic Exosome Platform-Product in Neurological Disorder Treatments; One Patent Also Grants Claims for an Isolated Population of Mesenchymal Stem Cells for Use in Treating ALS

On December 26, 2023, Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, provided an update on the grant and allowance of three patent applications for NurOwn® and NurOwn-Exosomes. The European Patent office granted patent No. 3105587 titled “Method of Qualifying of Cells” for a method of qualifying whether a cell population is a suitable therapeutic for treating amyotrophic lateral sclerosis (ALS) (Lou Gehrig’s disease). The patent also grants claims for an isolated population of mesenchymal stem cells (MSCs) for use in treating ALS. The Australian patent Office granted patent No. 2019252987 titled “Cell-Type Specific Exosomes and Use Thereof” for an isolated exosomes population derived from MSC-NTF cells, as well as a pharmaceutical composition for the treatment of neurodegenerative diseases. The Israel Patent Office announced the allowance of the same claims for application No. 277447, with an Acceptance date on December 01, 2023.

Login Or Register To Read Full Story